Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
6 studies found for:    9310283 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived HIV-1 Recombinant Envelope Glycoprotein (gp160)
Condition: HIV Infections
Intervention: Biological: gp160 Vaccine (Immuno-AG)
2 Completed A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160
Condition: HIV Infections
Interventions: Biological: Hepatitis B Vaccine (Recombinant);   Biological: gp160 Vaccine (MicroGeneSys)
3 Completed A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of a 200-mcg Dose
Condition: HIV Infections
Intervention: Biological: gp160 Vaccine (Immuno-AG)
4 Completed A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160
Condition: HIV Infections
Intervention: Biological: gp160 Vaccine (MicroGeneSys)
5 Completed A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of Accelerated Schedules
Condition: HIV Infections
Intervention: Biological: gp160 Vaccine (Immuno-AG)
6 Completed A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160
Condition: HIV Infections
Intervention: Biological: gp160 Vaccine (MicroGeneSys)

Indicates status has not been verified in more than two years